Several reports have successfully linked genetic defects (i.e., RAS pathway alterations, drug-metabolism related genes [FPGS, NT5C2, NR3C1, and PRPS1], transcription factor [TP53, IKZF1, CREBBP]) with ALL relapse (Mullighan et al., 2011; Tzoneva et al., 2013; Mar et al., 2014; Song et al., 2020). This evidence concerns the gene NT5C2 and acute lymphoblastic leukemia.